Cat. No. 1186
Alternative Name: Pituitary Adenylate Cyclase-Activating Polypeptide 1-38
Biological ActivityEndogenous neuropeptide showing considerable homology with vasoactive intestinal peptide (VIP) but with a greater potency for stimulation of adenylyl cyclase.
(Modifications: Lys-38 = C-terminal amide)
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Rawlings et al (1994) Pituitary adenylate cyclase-activating polypeptide increase [Ca2+]i in rat gonadotrophs through an inositol trisphosphate-dependent mechanism. J.Biol.Chem. 269 5680. PMID: 7907085.
Lazarovici et al (1998) The 38-amino-acid form of pituitary adenylate cyclase-activating polypeptide induces neurite outgrowth in PC12 cells that is dependent on protein kinase C and extracellular signal-regulated kinase but not on protein kinase A, nerve growth factor receptor tyrosine kinase, p21ras G protein, and pp60c-src cytoplasmic tyrosine kinase. Mol.Pharmacol. 54 547. PMID: 9730914.
Michel et al (1998) XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol.Rev. 50 143. PMID: 9549761.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: PACAP 1-38, supplier, Potently, stimulates, adenylyl, cyclases, stimulator, adenylate, Inositol, cAMP, Signaling, Signalling, Pituitary, Adenylate, Activating, Peptide, Receptors, PAC1, PACAP138
Find multiple products by catalog number
New Products in this Area
Potent neuropeptide S receptor (NPSR) antagonistTC OT 39
Nonpeptide oxytocin and V2 receptor partial agonist; also a V1a receptor antagonistTolvaptan
Potent and selective vasopressin V2 receptor antagonist; renoprotective and orally activeML 00253764 hydrochloride
Melanocortin MC4 receptor antagonist; brain penetrantGSK 1562590 hydrochloride
High affinity, selective urotensin II (UT) receptor antagonistMA 2029
Potent and selective, competitive motilin receptor antagonist; orally activeANQ 11125
Selective motilin receptor antagonist
November 15 - 19, 2014
Washington D.C., USA